--- title: "Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (688796.SH)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/688796.SH.md" symbol: "688796.SH" name: "Biocytogen Pharmaceuticals (Beijing) Co., Ltd." industry: "Biotechnology" datetime: "2026-05-19T23:45:36.611Z" locales: - [en](https://longbridge.com/en/quote/688796.SH.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688796.SH.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688796.SH.md) --- # Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (688796.SH) ## Company Overview Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group’s own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | CN Market | | Website | [www.biocytogen.com.cn](https://www.biocytogen.com.cn) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:08.000Z **Overall: B (0.36)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 6 / 81 | | Industry Median | C | | Industry Average | C | - **Style**: Growth - Stocks whose main business is in the growth stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 52.51% | | | Net Profit YoY | 536.56% | | | P/B Ratio | 18.57 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 42325514383.48 | | | Revenue | 1561033549.35 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 18.65% | A | | Profit Margin | 18.59% | A | | Gross Margin | 78.88% | A | | Revenue YoY | 52.51% | A | | Net Profit YoY | 536.56% | A | | Total Assets YoY | 0.00% | D | | Net Assets YoY | 172.63% | A | | Cash Flow Margin | 165.62% | B | | OCF YoY | 52.51% | A | | Turnover | 0.00 | E | | Gearing Ratio | 37.82% | B | ```chart-data:radar { "title": "Longbridge Financial Score - Biocytogen Pharmaceuticals (Beijing) Co., Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "52.51%", "rating": "" }, { "name": "Net Profit YoY", "value": "536.56%", "rating": "" }, { "name": "P/B Ratio", "value": "18.57", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "42325514383.48", "rating": "" }, { "name": "Revenue", "value": "1561033549.35", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "18.65%", "rating": "A" }, { "name": "Profit Margin", "value": "18.59%", "rating": "A" }, { "name": "Gross Margin", "value": "78.88%", "rating": "A" }, { "name": "Revenue YoY", "value": "52.51%", "rating": "A" }, { "name": "Net Profit YoY", "value": "536.56%", "rating": "A" }, { "name": "Total Assets YoY", "value": "0.00%", "rating": "D" }, { "name": "Net Assets YoY", "value": "172.63%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "165.62%", "rating": "B" }, { "name": "OCF YoY", "value": "52.51%", "rating": "A" }, { "name": "Turnover", "value": "0.00", "rating": "E" }, { "name": "Gearing Ratio", "value": "37.82%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 145.97 | 35/81 | 151.83 | 135.17 | 116.69 | | PB | 18.58 | 76/81 | 19.10 | 15.94 | 13.76 | | PS (TTM) | 27.14 | 78/81 | 28.23 | 25.37 | 21.90 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A | | 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A | | 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B | | 04 | RemeGen (688331.SH) | A | A | C | C | B | B | | 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688796.SH/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688796.SH/norm.md) - [Related News](https://longbridge.com/en/quote/688796.SH/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**